Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
| Project Name | Project Stage | Molecule Type | Host Species | Therapeutic Area | Indications |
| ROR1 mAb - 01 | Lead | Hematological Malignancy,AutoImmunity | Solid tumor,Blood tumor |
Expression analysis of human ROR1 on HEK293/Human ROR1 Stable Cell Line by FACS.
Cell surface staining was performed on HEK293/Human ROR1 Stable Cell Line or negative control cell using PE-labeled anti-human ROR1 antibody.
5e5 of anti-ROR1 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human ROR1 Protein, His Tag (Cat. No. RO1-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Anti-Human ROR1 mAb captured on CM5 chip via anti-mouse antibodies surface can bind Biotinylated Human / Cynomolgus / Rhesus macaque ROR1, His, Avitag (Cat. No. RO1-H82E6) with an affinity constant of 5.81 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| SIM-201 | SIM-201; SIM-0201 | Phase 1 Clinical | Jiangsu Simcere Pharmaceutical Co Ltd | Solid tumours | Details |
| NBE-002 | BI-3702025; NBE-002; PNU-159682-anti-ROR1 antibody drug conjugate | Phase 2 Clinical | Nbe-Therapeutics Ag | Solid tumours; Neoplasms; Triple Negative Breast Neoplasms | Details |
| GNC-035 quadr-specific antibody（baili） | GNC-035 | Phase 1 Clinical | Sichuan Baili Pharmaceutical Co Ltd | Solid tumours; Hematologic Neoplasms; Breast Neoplasms; Metastatic breast cancer | Details |
| LYL-797 | LYL-797 | Phase 1 Clinical | Lyell Immunopharma Inc | Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| PRGN-3007 | PRGN-3007 | Phase 1 Clinical | Precigen Inc | Hematologic Neoplasms; Solid tumours | Details |
| HG-030 | HG-030 | Phase 1 Clinical | Hitgen Inc | Solid tumours | Details |
| EMB-07 | EMB-07 | Phase 1 Clinical | Shanghai Epimab Biotherapeutics, Inc | Solid tumours; Neoplasms | Details |
| Zilovertamab | UC-961 | Phase 3 Clinical | University Of California San Diego, Oncternal Therapeutics Inc | Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Lymphatic Diseases; Immunoproliferative Disorders; Prostatic Neoplasms, Castration-Resistant; Immune System Diseases; Breast Neoplasms; Lymphoma, Mantle-Cell; Lymphoproliferative Disorders; Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
| LCB-71 | CS-5001; LCB-71; ABL-202 | Phase 1 Clinical | Legochem Biosciences Inc, Abl Bio Inc | Solid tumours; Hematologic Neoplasms; Lymphoma, B-Cell; Lymphoma | Details |
| ONCT-808 | ONCT-808 | Phase 2 Clinical | Oncternal Therapeutics Inc | Lymphoma, B-Cell; Neoplasms | Details |
| Zilovertamab vedotin | MK-2140; VLS-101 | Phase 3 Clinical | Oncternal Therapeutics Inc, University Of California San Diego | Lymphoma, Follicular; Carcinoma, Non-Small-Cell Lung; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma; Lymphoma, T-Cell; Burkitt Lymphoma; Waldenstrom Macroglobulinemia; Lymphoma, Mantle-Cell; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, B-Cell; Neoplasms; Triple Negative Breast Neoplasms; Pancreatic Neoplasms; Lymphoma, Large B-Cell, Diffuse; Carcinoma, Transitional Cell; Stomach Neoplasms; Lymphoma, B-Cell, Marginal Zone; Ovarian Neoplasms; Hematologic Neoplasms | Details |
| NVG-111 | NVG-111 | Phase 2 Clinical | NovalGen Ltd | Lymphoma, Mantle-Cell; Leukemia, Lymphocytic, Chronic, B-Cell | Details |
This web search service is supported by Google Inc.
A-Z
